Aura Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $41,669 | $59,515 |
| Marketable securities | 255,564 | 84,726 |
| Prepaid expenses and other current assets | 5,865 | 5,498 |
| Total current assets | 303,098 | 149,739 |
| Restricted cash and deposits | 768 | 768 |
| Right-of-use assets—operating lease | 14,560 | 15,828 |
| Other long-term assets | 1,167 | 471 |
| Property and equipment, net | 2,024 | 2,624 |
| Total Assets | $321,617 | $169,430 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | 1,722 | 1,549 |
| Short-term operating lease liability | 3,316 | 3,243 |
| Accrued expenses and other current liabilities | 16,299 | 13,591 |
| Total current liabilities | 21,337 | 18,383 |
| Long-term operating lease liability | 12,853 | 14,134 |
| Total Liabilities | 34,190 | 32,517 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.00001 par value, 500,000,000 and 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively, and 103,950,771 and 63,587,777 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1 | — |
| Additional paid-in capital | 919,897 | 617,433 |
| Treasury stock, at cost, 6,922,870 shares held at September 30, 2026 and no shares held at December 31, 2025 | (39,093) | — |
| Accumulated deficit | (591,806) | (480,418) |
| Accumulated other comprehensive loss | (1,572) | (102) |
| Total Stockholders’ Equity | 287,427 | 136,913 |
| Total Liabilities and Stockholders’ Equity | $321,617 | $169,430 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.